title: Therapeutic treatment with sustained-release platelet-rich plasma restores blood perfusion by augmenting ischemia-induced angiogenesis and arteriogenesis in diabetic mice.
abstract: OBJECTIVE
  The objective of this investigation was to establish the effectiveness of sustained-release platelet-rich plasma (PRP) on perfusion and neovascularization in diabetic murine hind limb ischemia.
  
  
  METHODS
  After surgery in streptozotocin-induced diabetic mice, the mice were randomly assigned to the following 4 experimental groups: control (C), 100 μl of the sustained-release form of platelet-poor plasma (PPP), 100 μl of the solution form of PRP (PRP-sol), and 100 μl of the sustained-release form of PRP (PRP-sr). Endpoint evaluations were: blood perfusion by laser Doppler perfusion imaging (LDPI), vascular density by anti-vWF, and mature vessel density by anti-smooth muscle actin antibody.
  
  
  RESULTS
  This study demonstrated that a sustained release of PRP increases the perfusion of ischemic tissue as measured by LDPI (57 ± 12; 56 ± 9; 72 ± 7, and 98 ± 4 for the C, PPP, PRP-sol, and PRP-sr groups, respectively; p < 0.05), capillary density (151 ± 16; 158 ± 12; 189 ± 39, and 276 ± 39 for groups C, PPP, PRP-sol, and PRP-sr, respectively; p < 0.05), and mature vessel density (28 ± 2; 31 ± 3; 52 ± 10, and 85 ± 13 for the C, PPP, PRP-sol, and PRP-sr groups, respectively; p < 0.05).
  
  
  CONCLUSIONS
  A sustained release of PRP containing potent angiogenic growth factors restores blood perfusion by stimulating angiogenesis and arteriogenesis.
authors.affiliation: Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
authors.forename: Shyamal Chandra
authors.initials: SC
authors.lastname: Bir
authors.forename: Jiro
authors.initials: J
authors.lastname: Esaki
authors.forename: Akira
authors.initials: A
authors.lastname: Marui
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakaguchi
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Kevil
authors.forename: Tadashi
authors.initials: T
authors.lastname: Ikeda
authors.forename: Masashi
authors.initials: M
authors.lastname: Komeda
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tabata
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Sakata
mesh_terms: D042501:Angiogenic Proteins / Q000097:blood; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002196:Capillaries / Q000503:physiopathology*; D002460:Cell Line; D049109:Cell Proliferation; D003692:Delayed-Action Preparations; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000097:blood / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D042783:Endothelial Cells / Q000378:metabolism; D006614:Hindlimb; D007150:Immunohistochemistry; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D007511:Ischemia / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D017078:Laser-Doppler Flowmetry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018482:Muscle, Skeletal / Q000098:blood supply*; D018919:Neovascularization, Physiologic; D053657:Platelet-Rich Plasma / Q000378:metabolism*; D011897:Random Allocation; D020127:Recovery of Function; D012039:Regional Blood Flow; D013997:Time Factors
chemical_list: D042501:Angiogenic Proteins; D001786:Blood Glucose; D003692:Delayed-Action Preparations; D036341:Intercellular Signaling Peptides and Proteins